HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Darin K Edwards Selected Research

2019-nCoV Vaccine mRNA-1273

3/2022Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
2/2022Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice.
1/2022Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
1/2022mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.
1/2022Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
12/2021Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
10/2021Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
10/2021COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.
10/2021mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.
8/2021Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Darin K Edwards Research Topics

Disease

9Infections
02/2022 - 05/2021
9COVID-19
02/2022 - 10/2020
4Inflammation (Inflammations)
02/2022 - 10/2020
4Weight Loss (Weight Reduction)
02/2022 - 08/2021
4Breakthrough Infections
02/2022 - 08/2021
2Severe Acute Respiratory Syndrome
03/2022 - 10/2021
2Pneumonia (Pneumonitis)
02/2022 - 08/2021
2Human Influenza (Influenza)
01/2022 - 01/2017
1Communicable Diseases (Infectious Diseases)
01/2022
1Acute Lung Injury
10/2021
1Persistent Infection
01/2021

Drug/Important Bio-Agent (IBA)

15VaccinesIBA
03/2022 - 01/2017
132019-nCoV Vaccine mRNA-1273IBA
03/2022 - 10/2020
5mRNA VaccinesIBA
02/2022 - 01/2017
3Neutralizing AntibodiesIBA
02/2022 - 10/2020
3Messenger RNA (mRNA)IBA
02/2022 - 01/2017
2COVID-19 VaccinesIBA
12/2021 - 10/2021
2Viral AntigensIBA
05/2021 - 01/2021
1Proteins (Proteins, Gene)FDA Link
02/2022
1N-(2-cyanoethylene)urea (BA 1)IBA
01/2022
1N-methyl-valyl-amiclenomycin (BA 2)IBA
01/2022
1Ad26COVS1IBA
01/2022
1Influenza Vaccines (Influenza Vaccine)FDA Link
01/2022
1RNA (Ribonucleic Acid)IBA
01/2022
1CytokinesIBA
01/2022
1aluminum sulfate (alum)IBA
10/2021
1AntibodiesIBA
10/2021
1Protein Subunit VaccinesIBA
10/2021
1AntigensIBA
10/2020
1Hemagglutinins (Hemagglutinin)IBA
01/2017